21 Ha’arba’a Street
341 articles with RedHill Biopharma
RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam to Savings Program for Uninsured or Underinsured Patients
This program allows RedHill to provide a discount on EnteraGam directly to eligible patients who are uninsured or underinsured.
The company confirmed that the Phase II study with BEKINDA 12 mg successfully met its primary endpoint.
Cash balance at the end of 2017 is expected to be approximately $45 million, with no debt.
Gross proceeds from the sale of the ADSs by RedHill before underwriting discounts and commissions and other offering expenses were approximately $22.5 million.
RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017.
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study With RHB-104 for Crohn's Disease
Top-line results are expected to be announced in mid-2018.
Gross proceeds from the sale of the ADSs by RedHill before underwriting discounts and commissions and other offering expenses are expected to be approximately $22.5 million.
The Company intends to use the proceeds from the offering to fund clinical development programs, for potential acquisitions, to support commercial operations and for general corporate purposes.
The Company will host a conference call on Monday, November 13, 2017, at 9:00 am EST to review the financial results and business highlights.
RIZAPORT is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines.
RHB-104 is a proprietary, orally-administered, potentially ground-breaking, antibiotic combination therapy with potent intracellular, antimycobacterial and anti-inflammatory properties.
The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.
RedHill Biopharma Accelerates RHB-104 Phase III Study In Crohn’s Disease With Top-Line Results Expected Mid-2018
RedHill Biopharma To Announce Top-Line Results From BEKINDA 12 Mg Phase II Study For IBS-D On October 3rd, 2017
RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering Its Combination Therapy For Hard-To-Treat Cancers
RedHill Biopharma Initiates Promotion Of Esomeprazole Strontium Delayed-Release Capsules 49.3 Mg In The U.S.
RedHill Biopharma Announces U.S. Commercialization Agreement For FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn’s Disease